Androgen Receptor Expression in Early Triple-Negative Breast Cancer: Clinical Significance and Prognostic Associations
Authors:
- Mirco PistelliMPMirco Pistelli
- Miriam CaramantiMCMiriam Caramanti
- Tommasina BiscottiTBTommasina Biscotti
- Alfredo SantinelliASAlfredo Santinelli
- Alessandra PagliacciAPAlessandra Pagliacci
- Mariagrazia De LisaMLMariagrazia De Lisa
- Zelmira BallatoreZBZelmira Ballatore
- Francesca RidolfiFRFrancesca Ridolfi
- Elena MaccaroniEMElena Maccaroni
- Raffaella BracciRBRaffaella Bracci
- Rossana BerardiRossana Berardi
- Nicola BattelliNBNicola Battelli
Open Access
Abstract
Background: Triple-negative breast cancers (TNBC) are characterized by aggressive tumour biology resulting in a poor prognosis. Androgen receptor (AR) is one of newly emerging biomarker in TNBC. In recent years, ARs have been demonstrated to play an important role in the genesis and in the development of breast cancer, although their prognostic role is still debated. In the present study, we explored the correlation of AR expression with clinical, pathological and molecular features and its impact on prognosis in early TNBC. Patients and Methods: ARs were considered positive in case of tumors with >10% nuclear-stained. Survival distribution was estimated by the Kaplan Meier method. The univariate and multivariate analyses were performed. The difference among variables were calculated by chi-square test. Results: 81 TNBC patients diagnosed between January 2006 and December 2011 were included in the analysis. Slides were stained immunohistochemically for estrogen and progesterone receptors, HER-2, Ki-67, ALDH1, e-cadherin and AR. Of the 81 TNBC samples, 18.8% showed positive immunostaining for AR, 23.5% and 44.4% of patients were negative for e-cadherin and ALDH1, respectively. Positive AR immunostaining was inversely correlated with a higher Ki-67 (p < 0.0001) and a lympho-vascular invasion (p = 0.01), but no other variables. Univariate survival analysis revealed that AR expression was not associated with disease-free survival (p = 0.72) or overall survival (p = 0.93). Conclusions: The expression of AR is associated with some biological features of TNBC, such as Ki-67 and lympho-vascular invasion; nevertheless the prognostic significance of AR was not documented in our analysis. However, since ARs are expressed in a significant number of TNBC, prospective studies in order to determine the biological mechanisms and their potential role as novel treatment target.Keywords
This publication has 45 references indexed in Scilit:
- The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activationBreast Cancer Research, 2012
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJournal of Clinical Investigation, 2011
- Targeting Androgen Receptor in Estrogen Receptor-Negative Breast CancerCancer Cell, 2011
- Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1The EMBO Journal, 2011
- Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal WomenClinical Cancer Research, 2011
- Androgen receptor expresion in breast cancer: Relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitorsBMC Cancer, 2008
- An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancerGenome Biology, 2007
- Androgen Receptor Expression in Estrogen Receptor–Negative Breast CancerAmerican Journal of Clinical Pathology, 2003
- The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parametersEuropean Journal of Cancer, 1996
- Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factorsThe Journal of Pathology, 1993